Three Stocks Flashing Strong Momentum Signals

BioXcel Therapeutics BTAI and Telos TLS saw significant increases in momentum scores this week, with BTAI's score jumping from 3.34 to 86.85 and TLS's score rising from 16.25 to 84.27. Jumia Technologies JMIA also saw a surge in momentum score, moving from 21.01 to 87.91. All three stocks have experienced significant price gains over the past week, with BTAI doubling and TLS and JMIA up 125% and 63%, respectively.

This week saw significant momentum gains for BioXcel Therapeutics (BTAI), Telos Corporation (TLS), and Jumia Technologies (JMIA), with their momentum scores surging considerably. BioXcel Therapeutics' score jumped from 3.34 to 86.85, Telos Corporation's score rose from 16.25 to 84.27, and Jumia Technologies' score moved from 21.01 to 87.91. These increases are reflective of substantial price gains over the past week, with BTAI doubling, TLS up 125%, and JMIA up 63%.

BioXcel Therapeutics (BTAI)

BioXcel Therapeutics experienced a 58.42% surge, trading at $230 million in volume, driven by the progress of its BXCL501 Phase 3 trial for at-home bipolar/schizophrenia agitation [1]. The Data Safety Monitoring Board (DSMB) endorsed continued testing, with 200 patients enrolled and Q3 2025 data pending. The company also raised $14 million in equity, boosting its cash to $35 million, but faces Nasdaq compliance deadlines and Q1 2025 losses of $7.3 million. A liquidity-focused trading strategy outperformed benchmarks by 137.53% since 2022, highlighting short-term volatility-driven returns.

Telos Corporation (TLS)

Telos Corporation achieved $36 million in Q2 2025 revenue, with 26% YoY growth driven by an 82% surge in security solutions sales [2]. The company's TSA PreCheck expansion to 415 centers and Xacta's FedRAMP "High" certification positioned TLS as a leader in government contracts. Telos repurchased $4 million worth of shares and maintained a 12.9% free cash flow margin, supporting Q3 2025 revenue guidance of $44-47 million. The company's focus on high-margin defense programs and R&D investments creates a growth flywheel, aligning with rising national security tech demand.

Jumia Technologies (JMIA)

Jumia Technologies experienced a significant increase in trading volume, with 3,834,380 shares traded, marking a 13% rise from the previous day's volume [3]. Institutional investors, including Cetera Investment Advisers and Mitsubishi UFJ Asset Management, have increased their stakes in Jumia. The stock last traded at $6.59, up from $5.78, with analysts setting new price targets. Jumia's debt-to-equity ratio of 0.15 and current ratio of 1.38 indicate a strong financial position.

Conclusion

The momentum gains for these three companies are driven by recent developments and strategic initiatives. BioXcel Therapeutics' progress in the BXCL501 trial and Telos Corporation's growth in security solutions and government contracts have fueled investor optimism. Jumia Technologies' increased trading volume and institutional stake increases signal growing interest from investors. As these companies continue to execute their strategies, investors can expect to see sustained momentum in their respective sectors.

References:
[1] https://www.ainvest.com/news/bioxcel-therapeutics-surges-58-42-230m-volume-ranks-452nd-market-activity-bxcl501-trial-progress-fuels-investor-optimism-2508/
[2] https://www.ainvest.com/news/telos-corporation-tls-turnaround-story-gaining-momentum-national-security-tech-2508/
[3] https://www.marketbeat.com/instant-alerts/jumia-technologies-nysejmia-sees-unusually-high-trading-volume-heres-what-happened-2025-08-11/